Axon Enterprise, Inc. (NASDAQ:AXON) Short Interest Up 14.7% in December

Axon Enterprise, Inc. (NASDAQ:AXON) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,570,000 shares, an increase of 14.7% from the December 15th total of 2,240,000 shares. Based on an average trading volume of 883,200 shares, the short-interest ratio is currently 2.9 days.

Axon Enterprise Trading Up 1.4 %

Axon Enterprise stock traded up $8.05 during trading hours on Friday, hitting $593.89. The stock had a trading volume of 533,566 shares, compared to its average volume of 1,040,913. The business’s 50 day simple moving average is $617.37 and its 200-day simple moving average is $459.99. Axon Enterprise has a one year low of $247.04 and a one year high of $698.67. The stock has a market cap of $45.28 billion, a price-to-earnings ratio of 153.46, a P/E/G ratio of 5.71 and a beta of 1.04. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Insider Transactions at Axon Enterprise

In other news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $639.69, for a total transaction of $639,690.00. Following the transaction, the director now directly owns 24,259 shares of the company’s stock, valued at approximately $15,518,239.71. This trade represents a 3.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,545 shares of company stock worth $30,721,337 over the last quarter. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds have recently added to or reduced their stakes in AXON. Insigneo Advisory Services LLC lifted its holdings in shares of Axon Enterprise by 1.4% during the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after purchasing an additional 22 shares during the period. Menard Financial Group LLC lifted its holdings in Axon Enterprise by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock worth $1,204,000 after buying an additional 24 shares during the period. PFG Investments LLC grew its position in shares of Axon Enterprise by 0.6% in the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after buying an additional 25 shares during the last quarter. Gladstone Institutional Advisory LLC increased its stake in shares of Axon Enterprise by 1.6% in the third quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 26 shares during the period. Finally, Mather Group LLC. raised its position in shares of Axon Enterprise by 3.7% during the third quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 27 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. JMP Securities upped their target price on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. TD Cowen started coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price objective for the company. Northland Securities raised their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Needham & Company LLC upped their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $504.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.